LYC-30937

September 6, 2016September 6, 2016

Phase 2 Trial of Oral Treatment for Ulcerative Colitis Now Recruiting

News

Lycera has announced the launch of a Phase 2 clinical trial to assess the effectiveness of its lead clinical-stage candidate, LYC-30937-EC (Enteric Coated), as a once daily oral treatment for patients with active ulcerative ... Read more

May 6, 2015September 28, 2016

University of Michigan Spinoff Lycera Begins First Trials Of U-M Developed & Licensed IBD Drug

IBD News, News

Lycera Corp., a University of Michigan spinoff biotech firm based on campus at Ann Arbor, has begun a Phase 1 clinical trial of the Inflammatory Bowel Disease (IBD Drug) LYC-30937 ... Read more

May 4, 2015May 4, 2015

Lycera Announces Initiation of Phase 1 Clinical Trial of Experimental Inflammatory Bowel Disease Therapy

IBD News, News

Lycera Corp., a biopharmaceutical company that develops novel oral immune modulators to treat autoimmune conditions and cancer, recently announced the start of a new Phase 1 clinical study of its ... Read more

March 27, 2015March 27, 2015

Lycera and Merck Reach Milestone in Collaboration for IBD Therapy

IBD News, News

Lycera Corp. has reached a milestone in its collaboration agreement with Merck on the study and development of small molecule therapeutic candidates to address a series of immune-mediated disorders, including inflammatory bowel diseases (IBD). ... Read more